Original Investigations

Psychopharmacology

, Volume 90, Issue 4, pp 468-470

First online:

Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance

  • Michael W. JannAffiliated withCollege of Pharmacy, The University of Texas at AustinDepartment of Pharmacology, The University of Texas Health Science Center at San AntonioSan Antonio State School
  • , Stephen R. SakladAffiliated withCollege of Pharmacy, The University of Texas at AustinDepartment of Pharmacology, The University of Texas Health Science Center at San AntonioDepartment of Psychiatry, The University of Texas Health Science Center at San AntonioSan Antonio State Hospital
  • , Larry EreshefskyAffiliated withCollege of Pharmacy, The University of Texas at AustinDepartment of Pharmacology, The University of Texas Health Science Center at San AntonioDepartment of Psychiatry, The University of Texas Health Science Center at San AntonioSan Antonio State Hospital
  • , Ann L. RichardsAffiliated withCollege of Pharmacy, The University of Texas at AustinSan Antonio State Hospital
  • , Charles A. HarringtonAffiliated withDepartment of Psychiatry, University of Texas Mental Science Institute
  • , Chester M. DavisAffiliated withDepartment of Psychiatry, University of Texas Mental Science Institute

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Plasma concentrations of haloperidol and its reduced metabolite (reduced haloperidol) were investigated in cigarette smokers (N=23) and nonsmokers (N=27). Steady-state plasma concentrations were obtained 12 h post bedtime dose. Haloperidol and reduced haloperidol concentrations were determined by RIA. Reduced haloperidol was separated by selective succinylation and liquid chromatography. Patients were clinically assessed with the Clinical Global Impression Scale (CGIS). Smokers had significantly lower haloperidol and reduced haloperidol plasma concentrations than nonsmokers (P<0.01, P<0.05). Clearance of haloperidol was significantly greater in smokers compared to nonsmokers (P=0.0052). CGIS assessments did not show significant differences between smokers and non-smokers. Plasma concentrations should be carefully monitored when patients either start or stop smoking.

Key words

Smoking Haloperidol Reduced haloperidol Plasma concentrations Clearance